Hikal Limited has submitted to the Exchange, the Unaudited Standalone and Consolidated financial results for the period ended Jun 30, 2025.
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 5.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hikal Limited reported weak Q1 FY26 results with standalone revenue from operations falling to Rs 3,804 million from Rs 4,068 million a year ago, a decline of about 6.5%. The company swung to a standalone loss before tax of Rs 307 million compared to a profit of Rs 70 million in Q1 FY25, and posted a standalone loss after tax of Rs 227 million (EPS of negative Rs 1.84) versus a profit of Rs 52 million earlier. Consolidated results mirrored this with a loss after tax of Rs 224 million versus a profit of Rs 51 million. The Pharmaceuticals segment turned from a profit of Rs 86 million to a loss of Rs 261 million, while the Crop Protection segment profit also fell to Rs 173 million from Rs 212 million. The statutory auditor (SRBC & Co LLP) issued an unmodified limited review opinion but drew attention to the pending environmental law matter before the Supreme Court, involving a stayed compensation claim of Rs 174.5 million.
The sharp swing to losses and segment weakness, especially in Pharmaceuticals, is likely to weigh on the stock. Investors should also track the Supreme Court environmental case, as an adverse ruling could trigger a sizeable compensation outflow beyond the Rs 50 million already deposited.